Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sweden-based Meda has entered into an agreement with US-based specialty pharmaceutical company Uluru for amlexanox 5% paste and OraDisc A. The agreement gives Meda exclusive rights to the products in most European countries, including Eastern Europe.
Subscribe to our email newsletter
Amlexanox 5% paste and OraDisc A are used for the treatment of canker sores and include the active ingredient amlexanox. OraDisc A is a novel patented mucoadhesive, water-erodible disc incorporating 2mg of amlexanox for the treatment and prevention of aphthous ulcers. The disc is applied to the sore and adheres to the mouth mucosa and the active ingredient is released locally.
Meda will pay an up-front of about E0.5 million for these rights. Total milestone payments are below E4.8 million.
Anders Lonner, CEO of Meda, said: “OraDisc is a unique product that fits our product portfolio in Europe. A specialist sales force is already established and we hope to be able to launch the product already during 2010.”